Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
By reprogramming the tumor microenvironment Kineta is developing an anti-VISTA immuno-oncology therapy for the treatment of a variety of cancers, including gastric, ovarian, lung and pancreatic cancers.
3T Biosciences has developed an immune response-guided approach for identifying pharmacologically active T cell receptors and their targets in solid tumors. With a pipeline of therapeutics targeting novel tumor antigens, 3T is seeking partners to advance these programs.
Targeting oncology and autoimmune diseases, Byondis takes its pipeline of development programs to clinical proof-of-concept and then seeks partnerships for later-stage clinical development and commercialization.
Glycostem, a clinical-stage company, which in 2017 published a successful phase 1 trial with naked natural killer (NK) cells for acute myeloid leukemia (AML), is about to launch its first pivotal trial using an off-the-shelf NK cell therapy for patients with AML.
Japanese company Synplogen uses technology based on over a decade of academic research to design and manufacture long and complex sequences of synthetic DNA. The company is also engaged in novel drug discovery and R&D of gene and cell therapies.
Noveome Biotherapeutics, Inc. is developing a new class of biologic consisting of the secretome from a novel population of cells derived from the amnion. The biological factors secreted by these cells have unique anti-inflammatory and neuroprotective effects. Presently, the company is looking for partners to drive clinical drug development of its lead product, ST266, in ophthalmic indications.
Building on its history of successful collaborations, Sanofi Pasteur, the vaccines global business unit of Sanofi, is seeking partners with a common drive for excellence and pursuit of innovation.
D&D Pharmatech funds the development of innovative therapeutic and diagnostic solutions to address critical unmet medical needs. D&D subsidiary Theraly Fibrosis is developing a novel treatment for chronic pancreatitis and other fibrotic indications, TLY012. Neuraly, another D&D subsidiary, recently launched a phase 2 study in Parkinson disease.
By acting directly on human cell machinery, Atriva Therapeutics’ lead candidate antiviral ATR-002 combines several advantages over existing therapies and could combat respiratory diseases such as influenza and COVID-19.
Amicoat’s environmentally friendly antimicrobial coating technology has a broad spectrum of activity with a low risk of provoking antibiotic resistance. The peptide-based technology effectively eliminates biofilms and can be applied to a wide range of medical devices to reduce healthcare-associated infections.
MiCAN Technologies has developed Mylc cells, human myeloid lineage cells for use in the study of infectious diseases caused by viruses. The company is also developing a human red blood-like cell product, Mpv. It is hoped that, together, these products will accelerate vaccine and drug development globally.
Aruvant is developing ARU-1801, a one-time, potentially curative gene therapy for sickle cell disease and β-thalassemia. In an ongoing clinical phase 1/2 study, ARU-1801, administered with only reduced intensity conditioning, has provided stable reductions in disease burden and opioid dependence.
Novadip is designing new treatment options for critical size defects, complex small size defects and surgically inaccessible tissue with its patented 3D tissue regeneration technology platform to transform the lives of patients with unmet medical needs.
inRegen’s personalized progenitor cell therapy injects autologous kidney cells (REACT) into patients’ damaged kidneys, where cells migrate and restore kidney function. The cell-based treatment is showing signs of promise in ongoing phase 2 trials.
Covering the whole production chain from the supply end to the value end, Nordic Biovian delivers a comprehensive and reliable manufacturing service, enabling the development of medical therapies.
Biotech start-up company NovaGo is developing human antibodies that stimulate nerve repair and regeneration following a stroke. The company’s lead candidate anti-Nogo-A antibody (NG004) is ready for phase 1 trials, and it is looking for partners to develop it through the clinic.
